Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists2026
2. 2Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.2025
3. 3Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study2023 · 29 citations
4. 4Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.2024
5. 5Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026